Purpose of the Study: The overall aim of the present work was to elucidate the effects of iontophoresis on assisting permeation/deposition of peptide dendrimers across/within human skin. Procedures: A series of peptide dendrimers containing arginine and histidine as terminal acids were synthesized and characterized. These dendrimers were subjected to passive and iontophoretic permeation studies across human epidermis. Results: The synthesized peptide dendrimers were found to be stable in epidermal, dermal and skin extracts up to 6 h. Passive diffusion studies revealed that none of the synthesized peptide dendrimers permeated human epidermis up to 6 h, although minute concentrations of low molecular weight dendrimers were detected in receptor medium at the end of 24 h. Application of iontophoresis significantly increased the permeation of all the tested peptide dendrimers across human skin in a molecular weight-dependent manner compared to simple passive diffusion. Electromigration was found to be the dominant mechanism behind the iontophoretic permeation of peptide dendrimers across human skin. Conclusions: The present study demonstrates that iontophoresis is an effective technique in enhancing the transdermal permeation of peptide dendrimers. Message of the Paper: This study foresees the possibility of applying peptide dendrimers in iontophoretic delivery of drugs and macromolecules across/within the skin.

1.
Chien YW: Transdermal therapeutic systems; in Robinson JR, Lee VHL (eds): Controlled Drug Delivery. New York, Marcel Dekker Inc, 1987, pp 523-549.
2.
Downing DT: Lipid and protein structure in the permeability barrier of mammalian epidermis. J Lipid Res 1992;33:301-313.
3.
Naik A, Kalia YN, Guy RH: Transdermal drug delivery: overcoming skin's barrier function. Pharm Sci Technol Today 2000;9:318-326.
4.
Prausnitz MR, Mitragotri S, Langer R: Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 2004;2:115-124.
5.
Venuganti VV, Perumal OP: Poly(amido-amine) dendrimers as skin penetration enhancers: influence of charge, generation and concentration. J Pharm Sci 2009;7:2345-2356.
6.
Cevc G, Vierl U: Nanotechnology and the transdermal route: a state of the art review and critical appraisal. J Control Release 2010;3:277-299.
7.
Venuganti VV, Sahdev P, Hildreth M, Guan X, Perumal O: Structure-skin permeability relationship of dendrimers. Pharm Res 2011;28:2246-2260.
8.
Mammen M, Choi SK, Whitesides GM: Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed 1998;20:2754-2794.
9.
Esfand R, Tomalia DA: Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today 2001;8:427-436.
10.
Gillies ER, Frechet JMJ: Dendrimers and dendritic polymers in drug delivery. Drug Discov Today 2005;1:35-43.
11.
El-Sayed M, Ginski M, Rhodes C, Ghandehari H: Transepithelial transport of poly(amido-amine) dendrimers across Caco-2 cell monolayers. J Control Release 2002;3:355-365.
12.
Kannan RM, Perumal OP, Kannan S: Dendrimers and hyperbranched polymers in drug delivery; in Labhateswar V, Pelecky L (eds): The Biomedical Applications of Nanotechnology. New Jersey, Wiley, 2005, pp 105-130.
13.
Bai S, Ahsan F: Synthesis and evaluation of pegylated dendrimeric nanocarrier for pulmonary delivery of low molecular weight heparin. Pharm Res 2009;3:539-548.
14.
Vandamme TF, Brobeck L: Poly(amidoam-ine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release 2005;1:23-38.
15.
Menjoge AR, Navath RS, Asad A, Kannan S, Kim CJ, Romero R, Kannan RM: Transport and biodistribution of dendrimers across human fetal membrane: implications for intravaginal administration of dendrimer-drug conjugates. Biomaterials 2010;18:5007-5021.
16.
Filipowicz A, Wolowiec S: Solubility and in vitro transdermal diffusion of riboflavin assisted by PAMAM dendrimers. Int J Pharm 2011;1-2:152-156.
17.
Wang Z, Itoh Y, Hosaka Y, Kobayashi I, Nakano Y, Maeda I, Umeda F, Yamakawa J, Kawase M, Yag K: Novel transdermal drug delivery system with polyhydroxyalkanoate and starbust polyamidoamine dendrimer. J Biosci Bioeng 2003;5:541-543.
18.
Chauhan AS, Sridevi S, Chalasani KB, Jain AK, Jain SK, Jain NK, Diwan PV: Dendrimer mediated transdermal delivery: enhanced bioavailability of indomethacin. J Control Release 2003;3:335-343.
19.
Na M, Yiyun C, Tongwen X, Yang D, Xiaomin W, Zhenwei L, Zhichao C, Guanyi H, Yunyu S, Longping W: Dendrimers as potential drug carriers. Part II - Prolonged delivery of ketoprofen by in vitro and in vivo studies. Eur J Med Chem 2006;5:670-674.
20.
Venuganti VVK, Perumal OP: Effect of poly-(amidoamine) (PAMAM) dendrimer on the skin permeation of 5-fluorouracil. Int J Pharm 2008;1-2:230-238.
21.
Parekh HS: The advance of dendrimers: a versatile targeting platform for gene/drug delivery. Cur Pharm Des 2007;27:2837-2850.
22.
Niederhafner P, Sebestik J, Jezek J: Peptide dendrimers. J Pept Sci 2005;11:757-788.
23.
Cloninger MJ: Biological applications of dendrimers. Curr Opin Chem Biol 2002;6:742-748.
24.
Mutalik S, Nayak UY, Kalra R, Kumar A, Kulkarni RV, Parekh HS: Sonophoresis-mediated permeation and retention of peptide dendrimers across human epidermis. Skin Res Technol 2012;1:101-117.
25.
Mutalik S, Hewavitharana AK, Shaw PN, Anissimov YG, Roberts MS, Parekh HS: Development and validation of a reversed-phase high-performance liquid chromatographic method for quantification of peptide dendrimers in human skin permeation experiments. J Chromatogr B 2009;29:3556-3562.
26.
Mutalik S, Parekh HS, Davies NM, Udupa N: A combined approach of chemical enhancers and sonophoresis for the transdermal delivery of tizanidine hydrochloride. Drug Deliv 2009;2:82-91.
27.
Kalia YN, Naik A, Garrison J, Guy RH: Iontophoretic drug delivery. Adv Drug Deliv Rev 2004;5:619-658.
28.
Parekh HS, Marano RJ, Rakoczy EP, Blanchfield J, Toth I: Synthesis of a library of polycationic lipid core dendrimers and their evaluation in the delivery of an oligonucleotide with hVEGF inhibition. Bioorg Med Chem 2006;14:4775-4780.
29.
Lai PM, Roberts MS: Epidermal iontophoresis II - Application of the ionic mobility-pore model to the transport of local anaesthetics. Pharm Res 1998;15:1579-1588.
30.
Schuetz YB, Naik A, Guy RH, Kalia YN: Effect of amino acid sequence on transdermal iontophoretic peptide delivery. Eur J Pharm Sci 2005;5:429-437.
31.
Chang SL, Hofmann GA, Zhang L, Deftos LJ, Banga AK: Transdermal iontophoretic delivery of salmon calcitonin. Int J Pharm 2000;1:107-113.
32.
Schuetz YB, Naik A, Guy RH, Vuaridel E, Kalia YN: Transdermal iontophoretic delivery of triptorelin. Pharm Res 2005;10:2175-2182.
33.
Burnette RR, Ongpipattanakul B: Characterization of the permselective properties of excised human skin during iontophoresis. J Pharm Sci 1987;10:765-773.
34.
Turner NG, Ferry L, Price M, Cullander C, Guy RH: Iontophoresis of poly-L-lysines: the role of molecular weight? Pharm Res 1997;10:1322-1331.
35.
Pikal MJ: The role of electroosmotic flow in transdermal iontophoresis. Adv Drug Deliv Rev 1992;9:201-237.
36.
Marro D, Kalia YN, Begoa Delgado-Charro M, Guy RH: Contributions of electromigration and electroosmosis to iontophoretic drug delivery. Pharm Res 2001:12:1701-1708.
37.
Potts RO, Guy RH: Predicting skin permeability. Pharm Res 1992;9:663-669.
38.
Magnusson BM, Anissimov YG, Cross SE, Roberts MS: Molecular size as the main determinant of solute maximum flux across the skin. J Invest Dermatol 2004;4:993-999.
39.
Hirvonen J, Guy RH: Transdermal iontophoresis: modulation of electroosmosis by polypeptides. J Control Release 1998;50:283-289.
40.
Wu X, Landfester K, Musyanovych A, Guy RH: Disposition of charged nanoparticles after their topical application to the skin. Skin Pharmacol Physiol 2010;3:117-123.
41.
Alvarez-Roman R, Naik A, Kalia YN, Fessi H, Guy RH: Visualization of skin penetration using confocal laser scanning microscopy. Eur J Pharm Biopharm 2004;2:301-316.
42.
Guy RH, Kalia YN, Delgado-Charro MB, Merino V, Lopez A, Marro D: Iontophoresis: electrorepulsion and electroosmosis. J Control Release 2000;64:129-132.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.